| INTRODUCTION
Postoperative sore throat is a common undesirable postoperative outcome following endotracheal intubation, and it affects up to 68% of patients undergoing general anesthesia. [1] [2] [3] [4] [5] [6] [7] It can persist for more than a week, and negatively impacts patient satisfaction and recovery. [7] [8] [9] Effective prevention of postoperative sore throat is thus needed.
Mucosal trauma and erosion due to endotracheal intubation and mucosal inflammation have been considered the aetiologies of postoperative sore throat. [10] [11] [12] [13] [14] Randomized controlled trials have suggested that anti-inflammatory agents, such as topical 15 or systemic corticosteroids, 16 topical nonsteroidal anti-inflammatory drugs, [17] [18] [19] and topical liquorice 20 can prevent postoperative sore throat.
Inhaled or aerosolized corticosteroids have been long used to treat asthma. Numerous randomized controlled trials have tested aerosolized corticosteroids for the prevention of postoperative sore throat. However, no systematic review has evaluated aerosolized corticosteroids as a prophylactic option for this postoperative complication.
Herein, we conducted a systematic review to examine the efficacy and safety of aerosolized corticosteroids in the prevention of Registration: PROSPERO (CRD42018086642) postoperative sore throat in adults undergoing tracheal intubation for general anesthesia.
| METHOD S
The conduct and reporting of this systematic review complied with the Cochrane Collaboration methodology 21 and PRISMA statement. 22 The protocol is registered at PROSPERO (CRD42018086642).
| Eligibility criteria
The eligibility criteria for the studies were: parallel group, randomized, controlled design comparing aerosolized corticosteroids with a non-analgesic or active control; aerosolized corticosteroids were 
| Search strategy
We searched Medline, EMBASE, China National Knowledge Infrastructure, and the Cochrane Central Register of Controlled Trials for eligible studies. Google Scholar and the reference lists of the relevant publications were examined to identify further eligible studies.
No language or publication status restrictions were imposed. The search strategy is shown in Table S1 . The search was updated on 13
May 2018.
| Study selection
The first author (AK), paired with one of the others (HM, RS), independently reviewed the articles retrieved through the search and selected the relevant ones. Disagreement was resolved via consensus.
| Data extraction
The same authors independently extracted the following data from 
| Risk of bias assessment
The same authors independently assessed the risk of bias using the Cochrane risk of bias assessment tool. 21 Given that sore throat is a subjective outcome, a study was judged to be at a low risk of performance bias when the participants were blinded to the interventions until all assessments were completed. Industry sponsorship or conflicts of interest were also checked. Inconsistencies were resolved through consensus. The original study authors were contacted for more information, if an e-mail address was available. The authors were considered unresponsive when no reply was obtained after three contact attempts.
| Statistical analysis
The primary outcomes examined were the incidence and severity of sore throat at 24 hours after surgery/extubation and the occurrence of adverse events in the study groups. Given that there is no universal definition for postoperative sore throat, the definitions of each study were accepted. Studies of postoperative sore throat have traditionally employed a four-level classification system to rate the severity of the condition: none, mild, moderate, and severe. When a study used this classification system, the incidence of sore throat was calculated from the sum of mild, moderate, and severe cases.
The secondary outcomes examined included the incidence of cough, hoarseness, and moderate or severe sore throat at 24 hours after surgery/extubation. The risk ratio (RR) and standardized mean difference (SMD) were calculated for dichotomous and continuous outcomes, respectively. When trials contained zero events in either arm, continuity correction was performed with the addition of 0.5 to each cell of 2 × 2 tables from the trial. 23 When the severity of sore throat was presented as medians with interquartile range, they were converted to the mean and standard deviation. 24 We pooled the data using the DerSimonian and Laird random-effects model. 25 Statistical heterogeneity was assessed using I 2 and Q statistics. 26 Because the number of studies for each outcome was smaller than 10, publication bias was not examined. 21 We assessed the quality of evidence and classified them as high, moderate, low, or very low, according to the GRADE (grading of recommendations, assessment, development, and evaluation) system.
Editorial Comment
In this trustworthy systematic review, the efficacy and safety of aerosolized corticosteroids in the prevention of postoperative sore throat in adults undergoing tracheal intubation for surgery was assessed. The authors found very low quantity and quality of evidence supporting use of aerosolized corticosteroids with no firm evidence for benefit or harm. This highlights the need for additional research within this topic.
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We performed primary analyses based on the type of comparator. We pooled the data into a single arm when a trial used more than one arm for a certain intervention. 21 
| RESULTS

| Overview of included studies
Our initial search yielded 2755 titles and abstracts. After applying our inclusion and exclusion criteria, 10 studies were potentially eligible. After evaluating the risk of bias, we excluded one quasirandomized study. 32 Nine randomized controlled trials involving 984 participants were finally included in our analysis 30, [33] [34] [35] [36] [37] [38] [39] [40] ( Figure S1 ).
The mean age for the study participants ranged from 22 to 53.9 years, and the proportion of women ranged from 20% to 100% ( topical ketamine, 36 and a combination of topical lidocaine and budesonide. 33 Two studies were performed in India 36, 38 and Iran, 30, 39 and one each in China, 33 France, 37 Egypt, 34 Pakistan, 40 and Thailand. 35 All trials, except one, were published in English full-text between 2003 and 2018, with the remaining one in Chinese. 33 Five studies used a four-level classification system to rate the severity of postoperative sore throat and confirm its presence. 30, 35, 36, 38, 39 Two studies reported the incidence of postoperative sore throat. 33, 40 Two studies used a visual analogue scale, 33, 37 and two used a 4-point Likert scale 34, 35 to assess the severity of postoperative sore throat. We contacted nine study authors for more details, and two responded with information.
| Risk of bias
Seven (78%) and three (33%) studies included adequate sequence generation and allocation concealment procedures, respectively (Table 2 ). Participants and outcome assessors were considered to be adequately blinded in five trials (56%) each. Five trials (56%) were free from conflicts of interest or sponsorship bias.
| Aerosolized corticosteroids vs non-analgesic controls
| Incidence of postoperative sore throat
Seven studies that included 606 participants provided data on the incidence of sore throat at 24 hours after surgery/extubation. Aerosolized corticosteroids were associated with a reduced incidence of postoperative hoarseness (RR, 0.39; 95% CI, 0.26-0.58; P < 0.001; df = 6; I 2 = 16.1%; Figure 1 ). The quality of the evidence for this outcome was very low; it was downgraded for risk of bias, imprecision, and potential publication bias, but was upgraded for the large effect size (Table 3 ).
| Severity of postoperative sore throat
Three trials, comprising 240 participants, reported the severity of sore throat at 24 hours after surgery/extubation. Aerosolized corticosteroids were found to likely be associated with decreased severity of postoperative sore throat (SMD, −0.96; 95% CI, −2.52, 0.59; P = 0.22; df = 2; I 2 = 96.3%; Figure 2 ). The quality of the evidence for this outcome was very low; it was downgraded for risk of bias, imprecision, and potential publication bias (Table 3) .
| Adverse events
Four studies attempted to report on adverse events; three studies and one other examined adverse events for 24 and 48 hours, respectively. All four studies reported that there were no adverse events related to aerosolized corticosteroids or the control. The quality of the evidence for this outcome was very low; it was downgraded for risk of bias and potential publication bias (Table 3) . 
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| Incidence of cough
Three studies that involved 226 participants provided data on the incidence of cough at 24 hours after surgery/extubation. Aerosolized corticosteroids were associated with a reduced incidence of postoperative cough (RR, 0.28; 95% CI, 0.15-0.51; P < 0.001; df = 2; I 2 = 0.0%; Figure S3 ).
| Incidence of hoarseness
Five studies that involved 506 participants examined the incidence of hoarseness at 24 hours after surgery/extubation. Aerosolized corticosteroids were associated with a reduced incidence of postoperative hoarseness (RR, 0.53; 95% CI, 0.38-0.74; P < 0.001; df = 4; I 2 = 0.0%; Figure 3 ).
| Subgroup, sensitivity, and trial sequential analysis
There was no significant subgroup difference associated with the type of aerosolized corticosteroids, comparator, or the time of giving corticosteroids, except for severity of postoperative sore throat (Table S2) . Our subgroup analysis found that the severity of postoperative sore throat was significantly improved in the subgroup that received budesonide before intubation and after extubation, with no intervention as the comparator. The results of the sensitivity analyses, excluding studies with unclear or a high risk of each type of bias, were consistent with those of the primary analyses. However, trial sequential analysis on the incidence of postoperative sore throat suggests that the cumulative z-curve did not cross the trial sequential monitoring boundary for benefit before reaching the required information size (3276 patients; TSA-adjusted 95% CI, 0.07-1.98; Figure S4 ); this suggests a false-positive effect of aerosolized corticosteroids on the prevention of postoperative sore throat.
| Aerosolized corticosteroids vs analgesic control
Four comparative effectiveness trials used analgesic agents as the comparator (Table S3 ). The comparators included systemic lidocaine (one study), 39 topical lidocaine (three studies), 33 
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Nebulized 4% lidocaine ketamine (one study), 36 and aerosolized budesonide combined with topical lidocaine (one study). 33 Aerosolized corticosteroids were no better than systemic lidocaine (incidence of sore throat, cough, and hoarseness), topical lidocaine (incidence of sore throat and hoarseness, and severity of sore throat), or topical ketamine (incidence of sore throat). While there was no significant difference between budesonide alone and budesonide combined with topical lidocaine in the incidence of sore throat, the severity of sore throat was significantly lower with budesonide combined with topical lidocaine compared with budesonide alone.
However, trial sequential analysis on the incidence of postoperative sore throat for each comparison suggests that the cumulative z-curve did not cross the conventional or trial sequential monitoring boundaries for benefit before reaching the required information size.
| Differences between the protocol and review
In addition, we conducted sensitivity analyses, in which the outcomes were presented as mean differences, and a trial sequential analysis on postoperative sore throat. We assessed the quality of evidence using the GRADE system.
| DISCUSSION
Our study suggests that aerosolized corticosteroids initiated before intubation in adults undergoing tracheal intubation for surgery under general anesthesia was associated with a decreased incidence of postoperative sore throat in comparison with the non-analgesic control.
The number needed to prevent postoperative sore throat when using aerosolized corticosteroids was 3 (95% CI 2-11), indicating a large prophylactic effect. Aerosolized corticosteroids significantly reduced the incidence of moderate or severe sore throat and were likely to mitigate the severity of postoperative sore throat. They also prevented cough and hoarseness after surgery. However, the evidence on the safety of aerosolized corticosteroids for preventing postoperative sore throat is limited. Our findings were robust throughout the sensitivity analysis. However, the quality of the evidence assessed with the GRADE system was found to be "very low" for each primary outcome, and the trial sequential analysis on the incidence of postoperative sore throat suggested that our finding could be false positive. Thus, further studies are needed before a firm conclusion can be established.
There was an inconsistency between the efficacy of aerosolized corticosteroids on the incidence and severity of postoperative sore throat. There are some potential explanations for this inconsistency.
First, the trials that failed to mitigate postoperative sore throat were more focused on the assessment of severity. The incidence of postoperative sore throat was not significantly reduced in three of the seven trials included in our analysis, while two of three included trials failed to show a significant reduction in severity. In addition, the number of trials included in the meta-analysis of severity was smaller than that for incidence (3 vs 7). This might have resulted in a wider confidence interval, although the point estimate of severity favoured aerosolized corticosteroids. Our analysis also indicates that moderate and severe postoperative sore throat was significantly reduced by aerosolized corticosteroids, which suggests that the severity of postoperative sore throat was mitigated. Along with these findings, aerosolized corticosteroids may decrease the severity of postoperative sore throat.
Mucosal inflammation around the tracheal tube cuff is considered to be one cause of tracheal morbidity. 11 According to this hypothesis, randomized controlled trials have examined topical and systemic anti-inflammatory agents, which are proven to be effective in preventing postoperative sore throat. 15, 18, 20, 30, 41 Systemic corticosteroids administered before elective extubation in the critical care setting, mitigate inflammatory laryngeal edema due to an endotracheal tube and prevent postextubation airway events. 42 Consistent with this evidence, our study suggests that aerosolized corticosteroids that are started preoperatively, reduce the incidence of postoperative airway complications.
Topical ketamine and lidocaine have been shown to prevent postoperative sore throat. 43, 44 Our study suggests that aerosolized corticosteroids were similar to topical ketamine or ketamine in preventing or ameliorating postoperative sore throat. However, the results of the trial sequential analyses suggest that these findings are indeterminate. We cannot draw a firm conclusion based on the current available evidence. More studies to determine the role of aerosolized corticosteroids for postoperative sore throat prevention are warranted.
All studies included in our analysis were published after implementation of the Consolidated Standards of Reporting Trials (CON-SORT) statement that requires trial investigators to report on the "harms" associated with interventions 45 ; only four of nine included studies reported any associated "harms." We need to remain cautious because the findings from these four studies may not always be identical to that from the other five. However, short-term inhaled corticosteroids for asthma during emergency department stays are associated with few significant adverse events. 46 Therefore, we need to use this alternative evidence until evidence on the safety of aerosolized corticosteroids for preventing postoperative sore throat is sufficiently accumulated.
This systematic review has some strengths. First, this is the first systematic review to assess the efficacy and safety of aerosolized corticosteroids for prophylaxis against postoperative sore throat. Our study found that aerosolized corticosteroids initiated before intubation are effective in preventing postoperative sore throat. Second, this review complied with the Cochrane methodology. We contacted T A B L E 3 GRADE summary of findings for aerosolized corticosteroids vs non-analgesic controls In conclusion, our study suggests that aerosolized corticosteroids may be superior to non-analgesic methods in preventing postoperative sore throat. However, the evidence on the efficacy and safety of aerosolized corticosteroids is limited and not definitive. Furthermore, aerosolized corticosteroids are similar to topical lidocaine for preventing and ameliorating postoperative sore throat.
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